70,364 results match your criteria Thrombocytopenia in Pregnancy


Maternal and perinatal outcomes of expectant treatment of severe preeclampsia

Rev Med Inst Mex Seguro Soc 2018 11 30;56(4):379-386. Epub 2018 Nov 30.

Instituto Mexicano del Seguro Social, Hospital de Ginecología y Obstetricia No. 3 “Dr. Víctor Manuel Espinoza de los Reyes Sánchez”, Unidad de Cuidados Intensivos. Ciudad de México, México

Background: In severe preeclampsia (SP), pregnancy interruption is the first recommendation. However, some patients receive expectant treatment.

Objetive: To determine maternal and perinatal results of expectant treatment of SP in the intensive care unit (ICU) of a high-specialty hospital. Read More

View Article
November 2018
6 Reads

Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer.

Anticancer Drugs 2018 Dec 4. Epub 2018 Dec 4.

Medical Oncology, Fujian Medical University Union Hospital.

The aim of this retrospective analysis was to evaluate the efficacy and toxicity of combination chemotherapy with paclitaxel, 5-fluorouracil, and leucovorin (TFL) as first-line treatment in patients with advanced gastric cancer (AGC). One hundred and thirteen patients were enrolled in the study who were confirmed to have AGC by histopathology. These patients were treated with TFL: paclitaxel at a dose of 135 mg/m as a 3-h intravenous infusion on day 1, LV 400 mg/m as an intravenous infusion over 2 h on day 1, followed by 5-fluorouracil 2400 mg/m as an infusion over a 46-h period on 3 consecutive days. Read More

View Article
December 2018

Heparin-induced thrombocytopenia suggested by microscopic examination of a below-knee amputation.

Transfusion 2018 Dec;58(12):2784-2785

Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, New York.

View Article
December 2018
2 Reads

Platelet transfusion practices in immune thrombocytopenia related hospitalizations.

Transfusion 2018 Dec 5. Epub 2018 Dec 5.

Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Division of Hematology/Oncology, Emory University School of Medicine, Atlanta, Georgia.

Background: The role of platelet transfusions in management of Immune Thrombocytopenia (ITP) remains controversial. Current guidelines recommend that platelet transfusions in ITP be reserved for catastrophic hemorrhage or invasive surgical procedures. This study assesses the nationwide platelet transfusion practices in hospitalized children and adults with ITP. Read More

View Article
December 2018
1 Read

Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report.

J Pharm Health Care Sci 2018 29;4:29. Epub 2018 Nov 29.

1Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602 Japan.

Background: To our knowledge, no studies have evaluated the safety of carboplatin (CBDCA)-based chemotherapy in hemodialysis patients > 80 years-old. In addition, the impact of CBDCA-based chemotherapy on such elderly patients' quality of life (QOL) is unknown. We report a case of gemcitabine plus CBDCA chemotherapy treatment in an 81-year-old man with metastatic urothelial carcinoma undergoing hemodialysis. Read More

View Article
November 2018

Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics.

Comput Biol Chem 2018 Oct 29;78:133-143. Epub 2018 Oct 29.

Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China. Electronic address:

Juvenile myelomonocytic leukaemia, an aggressive myeloproliferative neoplasm, is characterized by thrombocytopenia, splenomegaly, fever and excess myelomonocytic cells. Approximately 35% of patients with JMML occur D61Y mutation in PTPN11, and it increases the activity of the protein. However, the effect of the D61Y mutation on SHP2 conformations in molecular basis is poorly understood. Read More

View Article
October 2018

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.

PLoS One 2018 3;13(12):e0208102. Epub 2018 Dec 3.

Department of Woman, Child and General and Special Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.

Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is needed to remove iron excess and to contain bone-mass loss. Deferasirox is the most recent oral iron chelator that prevents transfusion related iron overload complications. Read More

View Article
December 2018

Prospective Evaluation of a Rapid Functional Assay for Heparin-Induced Thrombocytopenia Diagnosis in Critically Ill Patients.

Crit Care Med 2018 Nov 30. Epub 2018 Nov 30.

Division of Hematology Laboratory, Thrombosis and Hemostasis Center, Tenon Hospital, APHP.6, Sorbonne Université, HUEP Paris, France.

Objectives: Overdiagnosis of heparin-induced thrombocytopenia remains an unresolved issue in the ICU leading to the unjustified switch from heparin to alternative anticoagulants or delays in anticoagulation. Platelet function assays significantly improve the specificity of heparin-induced thrombocytopenia diagnosis, but they are not readily available, involve technical difficulties and have a long turnaround time. We evaluated the performance of a rapid and easy to perform functional assay for heparin-induced thrombocytopenia diagnosis in ICU patients, known as "heparin-induced multiple electrode aggregometry. Read More

View Article
November 2018

Severe fever with thrombocytopenia syndrome in China.

Lancet Infect Dis 2018 Nov 24;18(11):1180-1181. Epub 2018 Oct 24.

Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address:

View Article
November 2018

Beyond thrombocytopaenia, haemorrhage and shock: the expanded dengue syndrome.

Pathog Glob Health 2018 Dec 3:1-11. Epub 2018 Dec 3.

c Department of Parasitology, Faculty of medicine , University of Colombo , Colombo , Sri Lanka.

Dengue infection classically presents with fever, thrombocytopaenia, and varying degrees of plasma leakage, giving rise to shock. However, a myriad of other manifestations, involving the cardiovascular system, the nervous system, the liver, the kidneys, the gut and the haematological system have been reported in dengue. This review summarizes these varied presentations. Read More

View Article
December 2018
3 Reads

Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysis.

Platelets 2018 Dec 3:1-11. Epub 2018 Dec 3.

a Department of Hematology and Oncology , Graduate School of Medicine, Kyoto University , Kyoto , Japan.

Recent studies have indicated that medical options without splenectomy, such as rituximab (RTX) or thrombopoietin receptor agonists (TPO-RAs), can be effective to treat persistent or chronic primary immune thrombocytopenia (ITP). However, it remains to be determined which of these strategies should be the first choice after the first-line treatment for newly diagnosed ITP. We performed a systematic review and network meta-analysis to establish a clinically meaningful hierarchy of the efficacy and safety of medical treatments for persistent or chronic ITP in adults. Read More

View Article
December 2018
2 Reads

Emerging role of stem cell memory-like T cell (TSCM) in immune thrombocytopenia.

Scand J Immunol 2018 Dec 1:e12739. Epub 2018 Dec 1.

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.

Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by autoantibody-mediated platelet destruction. Multiple factors have been implicated in ITP pathogenesis, including T-lymphocyte dysfunctions. Increasing studies have indicated that stem cell memory-like T cell (TSCM) plays an important role in the development of multiple autoimmune diseases. Read More

View Article
December 2018
1 Read
1.882 Impact Factor

Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature.

eNeurologicalSci 2018 Dec 9;13:26-30. Epub 2018 Nov 9.

Department of Neurology, University Hospital of Heraklion, University of Crete, Greece.

Stroke is a frequent occurrence among patients suffering from systemic lupus erythematosus (SLE), but it rarely occurs as the initial manifestation of the disease. We here present the case of a 37 year-old patient who developed an acute cerebellar ischemic stroke as initial event of SLE: elevated partial thromboplastin time and ESR, thrombocytopenia, anti-ds-DNA, anti-SSA, anti-JO-1, and the lupus anticoagulant were detected, and the diagnosis of SLE was established. In addition, we reviewed the literature in order to clarify the demographic, clinical, imaging and outcome characteristics of such a presentation, and found 10 similar cases. Read More

View Article
December 2018
1 Read

Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation.

J Gastrointest Oncol 2018 Oct;9(5):922-935

Department of Surgery, NYU School of Medicine, New York, NY, USA.

Background: Half of patients with pancreatic adenocarcinoma (PC) present with regionally advanced disease. This includes borderline resectable and locally advanced unresectable tumors as defined by current NCCN guidelines for resectability. Chemoradiation (CH-RT) is used in this setting in attempt to control local disease, and possibly downstage to resectable disease. Read More

View Article
October 2018

A giant splenic hamartoma associated with hematologic disorders: A case report.

Ann Med Surg (Lond) 2018 Dec 16;36:199-202. Epub 2018 Nov 16.

Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Dr. Ignacio Morones Prieto O 3000, Monterrey, 64710, Mexico.

Introduction: Splenic hamartoma is a primary benign tumor of the spleen, with approximately 150 cases documented in the literature to date, with only a few cases associated with symptoms and hematologic disorders.

Presentation Of Case: A 49-year-old female with no past medical history, presented to the emergency department complaining of a three-month history of intermittent abdominal pain and 12 kg of weight loss. Physical examination revealed abdominal distension and a big palpable and painless mass on the left side of her abdomen measuring 14 cm. Read More

View Article
December 2018

Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide.

Endocr J 2018 Nov 30. Epub 2018 Nov 30.

Department of Molecular and Cellular Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Diazoxide is recognized as an effective medical treatment for insulinoma. However, due to its adverse effects, such as fluid retention, it is sometimes difficult to employ diazoxide at an effective dose in clinical practice. This study aimed to clarify the clinical factors, which may affect efficacy and safety of the diazoxide treatment. Read More

View Article
November 2018
2 Reads

Visceral Mycoses in Autopsied Cases in Japan from 1989 to 2013.

Med Mycol J 2018 ;59(4):E53-E62

Department of Pathology, Kitasato University School of Medicine.

Background And Methods: Our group has continuously studied the epidemiology of visceral mycoses (VM) among autopsy cases in Japan from 1989 to 2013.

Results: First, from a total of 11,149 autopsied cases, 571 (5.1%) cases of VM were observed in 2013. Read More

View Article
January 2018

Drug-associated thrombocytopenia.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):576-583

Transfusion Medicine, Medical Faculty of Tubingen, University of Tubingen, Tubingen, Germany.

Many drugs have been implicated in drug-induced immune thrombocytopenia (DITP). Patients with DITP develop a drop in platelet count 5 to 10 days after drug administration with an increased risk of hemorrhage. The diagnosis of DITP is often challenging, because most hospitalized patients are taking multiple medications and have comorbidities that can also cause thrombocytopenia. Read More

View Article
November 2018
2 Reads

Evidence-based management of immune thrombocytopenia: ASH guideline update.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):568-575

Imperial College Health Care NHS Trust, Hammersmith Hospital, London, UK.

In 1996 and 2011, the American Society of Hematology (ASH) supported efforts to create guidelines for the diagnosis and management of patients with immune thrombocytopenia (ITP). These guidelines used different approaches to arrive at recommendations for testing and treatment. Despite differences in methodology, in both cases there was a paucity of randomized trials to inform recommendations. Read More

View Article
November 2018
5 Reads

How do we diagnose immune thrombocytopenia in 2018?

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):561-567

Michael G. DeGroote School of Medicine, Department of Medicine and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

In this report, we will review the various clinical and laboratory approaches to diagnosing immune thrombocytopenia (ITP), with a focus on its laboratory diagnosis. We will also summarize the results from a number of laboratories that have applied techniques to detect anti-platelet autoantibodies as diagnostic tests for ITP. Although there is considerable variability in methods among laboratories, there is general agreement that platelet autoantibody testing has a high specificity but low sensitivity. Read More

View Article
November 2018
1 Read

Clinical and laboratory diagnosis of TTP: an integrated approach.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):530-538

Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Thrombotic thrombocytopenia purpura (TTP) is a rare, life-threatening disease with an incidence of approximately 2 persons per million per year. It is characterized by severe deficiency of the von Willebrand cleaving protease, ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), leading to formation of platelet-rich thrombi in the microvasculature. Prompt initiation of appropriate therapy, particularly plasma exchange, may be life-saving. Read More

View Article
November 2018
3 Reads

Preventing and managing catastrophic bleeding during extracorporeal circulation.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):522-529

Department of Anesthesia, University of Toronto, Toronto, ON, Canada.

The use of extracorporeal circulation for cardiac surgery and extracorporeal life support poses tremendous challenges to the hemostatic equilibrium given its diametric tendency to trigger hyper- and hypocoagulopathy. The necessity of anticoagulant therapy to counteract the hemostatic activation by the extracorporeal circuitry compounded by unfavorable patient and surgical factors significantly increase the risk of catastrophic bleeding in patients who require extracorporeal circulation. Preoperative measures, such as stratification of high-risk bleeding patients, and optimization of the modifiable variables, including anemia and thrombocytopenia, provide a crude estimation of the likelihood and may modify the risk of catastrophic bleeding. Read More

View Article
November 2018

Adult and pediatric mechanical circulation: a guide for the hematologist.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):507-515

Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.

Mechanical circulatory support (MCS) is the overarching term that encompasses the temporary and durable devices used in patients with severe heart failure. MCS disturbs the hematologic and coagulation system, leading to platelet activation, activation of the contact pathway of coagulation, and acquired von Willebrand syndrome. Ischemic stroke and major hemorrhage occur in up to 30% of patients. Read More

View Article
November 2018

Anticoagulating patients with high-risk acquired thrombophilias.

Authors:
Leslie Skeith

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):439-449

Division of Hematology and Hematological Malignancies, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada; and Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.

Antiphospholipid syndrome (APS), heparin-induced thrombocytopenia, and paroxysmal nocturnal hemoglobinuria are 3 acquired thrombophilias that carry a high risk of venous and arterial thromboembolism. Management of these conditions has largely included anticoagulation with a vitamin K antagonist after an initial period of a parenteral anticoagulant, for as long as the thrombotic risk is still present. The available evidence for the use of direct oral anticoagulants (DOACs) is limited and primarily consists of case series and cohort studies, which are summarized in this chapter. Read More

View Article
November 2018

Pediatric ITP: is it different from adult ITP?

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):405-411

Department of Pediatrics, Hematology/Oncology Section, Baylor College of Medicine, Houston, TX.

Immune thrombocytopenia (ITP) has historically been thought to occur in 2 distinct forms: childhood ITP and adult ITP. This division is based largely on the presumption that childhood ITP is often benign and self-limited, whereas ITP in adults tends to be more chronic and difficult to treat. Although data exist to justify a different approach to the diagnosis and treatment in young children and the elderly, ITP in older children, adolescents, and younger adults is likely to share more similar pathology. Read More

View Article
November 2018
2 Reads

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):318-325

Division of Translational Medicine & Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy (MCD) with systemic inflammation, cytopenias, and life-threatening multiple organ dysfunction resulting from a cytokine storm often driven by interleukin 6 (IL-6). Uncontrolled human herpesvirus-8 (HHV-8) infection causes approximately 50% of MCD cases, whereas the etiology is unknown in the remaining HHV-8-negative/idiopathic MCD cases (iMCD). Read More

View Article
November 2018

Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish.

Blood Adv 2018 Dec;2(23):3418-3427

Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI.

The NFE2 transcription factor is expressed in multiple hematopoietic lineages with a well-defined role in regulating megakaryocyte biogenesis and platelet production in mammals. Mice deficient in NFE2 develop severe thrombocytopenia with lethality resulting from neonatal hemorrhage. Recent data in mammals reveal potential differences in embryonic and adult thrombopoiesis. Read More

View Article
December 2018

Severe Sinus Bradycardia in Puumala virus infection.

Int J Infect Dis 2018 Nov 29. Epub 2018 Nov 29.

Service de Médecine Interne, CHRU de Besançon, Besançon, France. Electronic address:

Puumala orthohantavirus (PUUV) is the most prevalent of the four species of zoonotic hantaviruses found in Europe, causing nephropathia epidemica, a mild form of hemorrhagic fever with acute kidney injury that presents with elevated serum creatinine level, proteinuria and hematuria. The febrile phase of the infection begins by flu-like syndrome, visual disturbance. Laboratory results can show thrombocytopenia. Read More

View Article
November 2018
1 Read

Dosage escalation of intravenous cyclophosphamide in cats with cancer.

Vet J 2018 Dec 16;242:39-43. Epub 2018 Oct 16.

Queensland Veterinary Specialists, 263 Appleby Road, Stafford Heights, QLD 4053, Australia.

Cyclophosphamide is an alkylating agent used as chemotherapy for cats with lymphoma, carcinomas and sarcomas. Clinical and pharmacokinetic studies of cyclophosphamide in normal and tumor-bearing cats have shown minimal toxicity and cyclophosphamide at clinically used dosages rarely requires dosage adjustment or treatment delays. Dose intensity appears important for treatment of most cancers; the aim of this study was to perform a modified dose escalation study of cyclophosphamide to establish the maximally tolerated dosage (MTD) for intravenous cyclophosphamide in cats. Read More

View Article
December 2018

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Semin Hematol 2018 Oct 5;55(4):248-255. Epub 2018 Jun 5.

Institute of Hematology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

Recently, the myelofibrosis secondary to PV and ET prognostic model (MYSEC-PM) was introduced to assess prognosis in myelofibrosis (MF) secondary to polycythemia vera and essential thrombocythemia (post-PV and post-ET MF), replacing the International Prognostic Scoring System (IPSS) and/or Dynamic IPSS (DIPSS) that was applied for primary MF (PMF). In a cohort of 421 ruxolitinib (RUX)-treated patients (post-PV and post-ET MF: 44.2%), we evaluated the following: (1) disease phenotype, responses, and toxicity to RUX; and (2) performance of the MYSEC-PM in post-PV or post-ET MF. Read More

View Article
October 2018

Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.

Semin Hematol 2018 Oct 13;55(4):189-196. Epub 2017 Oct 13.

Haematology Department, Hospital Clínico Universitario, Salamanca, Spain.

Bortezomib-melphalan-prednisone combination is one of the standards of care for nontransplant eligible patients with newly diagnosed multiple myeloma. However, bortezomib intravenous (twice weekly for 4 cycles then weekly for 5 cycles) results in ~13% of patients with grade 3-4 peripheral neuropathy. Bortezomib subcutaneous (SQ) and weekly delivery, improves tolerability without impairment of efficacy. Read More

View Article
October 2018

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.

Clin Gastroenterol Hepatol 2018 Nov 28. Epub 2018 Nov 28.

Institute for Gastrointestinal and Liver Diseases, Shin-yurigaoka General Hospital, Kawasaki, Japan.

Background & Aims: Platelet transfusion is used to prevent hemorrhagic events in patients with thrombocytopenia undergoing invasive procedures, but there are many disadvantages. We evaluated the efficacy and safety of lusutrombopag in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures.

Methods: We performed a double-blind, parallel-group, phase 3 study of 96 patients with chronic liver disease and thrombocytopenia (platelet counts below 50,000/μL) undergoing invasive procedures from October 2013 to May 2014 at 81 centers in Japan. Read More

View Article
November 2018

Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists.

J Cardiothorac Vasc Anesth 2018 Oct 26. Epub 2018 Oct 26.

Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA. Electronic address:

Patients undergoing cardiovascular surgery may be exposed to heparin before surgery, during cardiopulmonary bypass (CPB), or in the immediate postoperative period. For this reason, cardiovascular surgery patients are at increased risk for heparin-induced thrombocytopenia (HIT), occurring in 1 to 3% of patients. The diagnosis of HIT can be difficult, if based solely on the development of thrombocytopenia, because cardiac surgical patients have multiple reasons to be thrombocytopenic. Read More

View Article
October 2018

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.

Lancet Haematol 2018 Dec;5(12):e628-e640

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Bortezomib with lenalidomide and dexamethasone (VRd) is a standard regimen for the front-line treatment of multiple myeloma. Panobinostat is approved in combination with bortezomib and dexamethasone in patients with myeloma who 'have been given at least two previous regimens including bortezomib and an immunomodulatory agent. We aimed to determine the maximum tolerated dose of a new regimen combining VRd with panobinostat in patients with newly diagnosed multiple myeloma. Read More

View Article
December 2018
1 Read

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Lancet Haematol 2018 Dec;5(12):e609-e617

Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address:

Background: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. We aimed to determine the outcome of dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R), an intensive infusional treatment regimen, in untreated aggressive B-cell lymphoma with MYC rearrangement. Read More

View Article
December 2018

[Role of Inflammasome in Children's Immune Thrombocytopenia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Dec;26(6):1742-1745

Department of Infection, Xuzhou Children's Hospital, Xuzhou 221006, Jiangsu Province, China.E-mail:

Objective: To explore the role and the mechanism of NLRP3 inflammasome in children's immune thrombocytopenia (ITP).

Methods: Twenty-one children suffered from ITP were enrolled in ITP group, 10 healthy children were selected in control group. Peripheral blood mononuclear cells (PBMNC) were isolated from ITP children and healthy controls. Read More

View Article
December 2018

[Clinical Charcteristics and Prognostic Analysis of 28 cases of Pediatric Myelodysplastic Syndrome].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Dec;26(6):1695-1701

Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China.E-mail:

Objective: To analyze the clinical features and prognosis of 28 children with myelodysplastic syndrome (MDS) and to screen the high risk factors affecting the prognosis so as to provide the new ideas for standard of clinical diagnosis and therapy.

Methods: The clinical data of 28 children with newly diagnosed MDS treated in our hospital from March 1994 to July 2016 were analyzed retrospectively, the features of disease onset and the results of laboratory examination were summarized, all MDS children were followed up, the prognosis and the high risk factors affecting the prognosis were evaluated.

Results: In all 28 MDS children, the ratio of male to female was 1. Read More

View Article
December 2018

Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.

Acta Haematol 2018 Dec 5;141(1):43-53. Epub 2018 Dec 5.

Department of Hematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science, Xiangyang,

Background/aims: The aim of this work was to investigate the efficacy and predictive factors of CLAG treatment in refractory or relapsed (R/R) acute myeloid leukemia (AML) patients.

Methods: Sixty-seven R/R AML patients were enrolled in this prospective cohort study and treated by a CLAG regimen: 5 mg/m2/day cladribine (days 1-5), 2 g/m2/day cytarabine (days 1-5), and 300 μg/day filgrastim (days 0-5). The median follow-up duration was 10 months. Read More

View Article
December 2018
1 Read

Vancomycin-induced severe thrombocytopenia in a young infant.

Rev Soc Bras Med Trop 2018 Nov-Dec;51(6):873-875

Department of Pharmacy, Xiamen Maternity and Child Care Hospital, Xiamen, Fujian, China.

Vancomycin is a first-line drug for treating methicillin-resistant Staphylococcus aureus. Thrombocytopenia is a rare adverse reaction to vancomycin treatment, and there are no reports of vancomycin-induced thrombocytopenia (VIT) in infants. We describe the case of a 3-month-old girl who was diagnosed with purulent meningitis. Read More

View Article
April 2018
4 Reads

CHARACTERISTICS OF DIARRHEAL DISEASE COMPLICATED WITH HEMOLYTIC UREMIC SYNDROME AMONG CHILDREN IN GEORGIA, 2009-2016.

Georgian Med News 2018 Oct(283):123-129

Infectious Diseases, AIDS and Clinical Immunology Research Center; Tbilisi State Medical University; M. Iashvili Children's Central Hospital; 4National Center for Disease Control and Public Health, Tbilisi, Georgia.

Shiga toxin-producing Escherichia coli (STEC) causes illness ranging from mild diarrhea to bloody diarrhea, to the hemolytic uremic syndrome (HUS), which manifests with a triad of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. Surveillance of HUS and bloody diarrhea is not performed in Georgia. The primary objective of our study was to determine the annual incidence of diarrheal diseases. Read More

View Article
October 2018
1 Read

Preoperative Thrombocytopenia May Predict Poor Surgical Outcome after Extended Hepatectomy.

Can J Gastroenterol Hepatol 2018 1;2018:1275720. Epub 2018 Nov 1.

Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.

Background: It is a novel idea that platelet counts may be associated with postoperative outcome following liver surgery. This may help in planning an extended hepatectomy (EH), which is a surgical procedure with high morbidity and mortality.

Aim: The aim of this study was to evaluate the predictive potential of platelet counts on the outcome of EH in patients without portal hypertension, splenomegaly, or cirrhosis. Read More

View Article
November 2018

Predicting 30-day mortality in patients with sepsis: An exploratory analysis of process of care and patient characteristics.

J Intensive Care Soc 2018 Nov 19;19(4):299-304. Epub 2018 Feb 19.

Nottingham University Hospitals NHS Trust, UK.

Background: Sepsis represents a significant public health burden, costing the NHS £2.5 billion annually, with 35% mortality in 2006. The aim of this exploratory study was to investigate risk factors predictive of 30-day mortality amongst patients with sepsis in Nottingham. Read More

View Article
November 2018

Risk Factors in Predicting Prognosis of Neonatal Bacterial Meningitis-A Systematic Review.

Front Neurol 2018 20;9:929. Epub 2018 Nov 20.

Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.

Neonatal bacterial meningitis is a severe infection with high mortality and morbidity. It is necessary to identify factors associated with a high risk of a poor prognosis so that we can prevent them with more appropriate treatments. This study was performed to summarize the prognostic factors known to predict adverse outcomes in neonatal bacterial meningitis. Read More

View Article
November 2018

Combination peptide immunotherapy suppresses antibody and helper T cell responses to the major human platelet autoantigen GPIIb/IIIa in HLA-transgenic mice.

Haematologica 2018 Dec 4. Epub 2018 Dec 4.

Institute of Medical Sciences, Ashgrove Road West, University of Aberdeen, UK

Platelet destruction in immune thrombocytopenia is caused by autoreactive antibody and T cell responses, most commonly directed against platelet glycoprotein IIb/IIIa. Loss of self-tolerance in the disease is also associated with deficient activity of regulatory T cells. Having previously mapped seven major epitopes on platelet glycoprotein IIIa that are recognised by helper T cells from patients with immune thrombocytopenia, the aim was to test whether peptide therapy with any of these sequences, alone or in combination, could inhibit responses to the antigen in humanized mice expressing HLA-DR15. Read More

View Article
December 2018

A study of clinical, hematological, and biochemical profiles of patients with dengue viral infections in Northwest Ethiopia: implications for patient management.

BMC Infect Dis 2018 Dec 4;18(1):616. Epub 2018 Dec 4.

Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Background: Dengue is one of the most common arboviral diseases with increased outbreaks annually in tropical and subtropical areas. In Ethiopia, there are no data regarding clinical, hematological and biochemical parameters which are very important in the clinical management of dengue patients. Hence this study was carried out to provide the first baseline data of clinical, hematological and biochemical profiles of patients infected with dengue virus. Read More

View Article
December 2018

Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects and .

Toxins (Basel) 2018 Dec 2;10(12). Epub 2018 Dec 2.

Laboratório de Bacteriologia, Instituto Butantan, São Paulo 05503900, Brasil.

Shiga toxin (Stx) producing (STEC) is responsible for causing hemolytic uremic syndrome (HUS), a life-threatening thrombotic microangiopathy characterized by thrombocytopenia, hemolytic anemia, and acute renal failure after bacterially induced hemorrhagic diarrhea. Until now, there has been neither an effective treatment nor method of prevention for the deleterious effects caused by Stx intoxication. Antibodies are well recognized as affinity components of therapeutic drugs; thus, a previously obtained recombinant human FabC11:Stx2 fragment was used to neutralize Stx2 in vitro in a Vero cell viability assay. Read More

View Article
December 2018

Leptospirose.

Rev Prat 2016 Oct;66(8):886-892

Maladies infectieuses et tropicales, groupe hospitalier La Pitié-Salpêtrière, Paris, France.

Leptospirosis. Leptospirosis is the first worldwide anthropozoonosis with an incidence of 1 000 000 cases per year. It is more frequently encountered in tropical areas but also can be diagnosed in tempered places. Read More

View Article
October 2016
1 Read

Complications somatiques de l’anorexie mentale. Elles sont responsables d’une mortalité élevée.

Rev Prat 2016 Feb;66(2):153-157

Clinique des maladies mentales et de l'encéphale, hôpital Sainte-Anne, Paris, France.

Medical complications of anorexia nervosa. Anorexia nervosa causes acute or chronic medical complications that can affect most organs: dermatologic complications, gastrointestinal complications (including constipation, delayed gastric emptying, rarely hepatitis), endocrine and bone (amenorrhea, infertility, hypoglycemia, delayed puberty, arrested growth, osteoporosis.. Read More

View Article
February 2016
1 Read

A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.

Cancer Chemother Pharmacol 2018 Dec 3. Epub 2018 Dec 3.

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China.

Purpose: The standard treatment for peripheral T-cell lymphomas (PTCLs) is undetermined. We designed a CHOPE/G regimen (cyclophosphamide, pirarubicin, vincristine, prednisolone, and etoposide alternating with a gemcitabine-based regimen) as the first-line treatment of PTCLs and compared with CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) and CHOPE (CHOP plus etoposide) regimen to evaluate the optimal chemotherapy regimen.

Methods: 116 previously untreated PTCL patients received CHOP (N = 46), CHOPE (N = 46), or CHOPE/G (N = 24) regimen at Peking University Cancer Hospital from 2009 to 2017 and were retrospectively analyzed. Read More

View Article
December 2018